Novo Nordisk is rated a strong buy, offering a 4.2% yield and trading at a 40% discount to fair value. NVO's growth is temporarily pressured by U.S. price cuts and competition, but volume and product expansion position it for double-digit growth from 2027 onward. The Wegovy franchise, including a high-performing pill, is outpacing competitors internationally, with robust pipeline milestones expected in 2026–2027.